{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-21-000027","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.542066+00:00","generated_at":"2026-06-29T21:18:31.092808+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prestige Consumer Healthcare Q1 revenue $269.2M (+17.3%), EPS $1.14 (+32.5%); raises FY22 outlook","bullets":["Revenue $269.2M, up 17.3% YoY; diluted EPS $1.14, up 32.5% vs prior year.","North American OTC revenue $242.4M; International OTC $26.8M, up 43% from $18.7M.","Raising FY22 guidance: revenue ~$1.045B+ (prev. $957-962M), adj. EPS $3.90+ (prev. $3.58+).","TheraTears acquisition closed July 1, expected to add ~$40M revenue and $0.07 EPS to FY22.","Net cash from ops $69.3M, free cash flow $67.8M; net debt ~$1.4B; refinanced term loan to 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-21-000027","json":"https://secwatch.observer/filing/0001295947-21-000027.json","markdown":"https://secwatch.observer/filing/0001295947-21-000027.md","text":"https://secwatch.observer/filing/0001295947-21-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594721000027/0001295947-21-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594721000027/pbh-20210805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T21:18:31.092808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}